linjc16/ctgov huggingface dataset:
Ankle Instability in Flamenco Dancers

Study Overview
=================
Brief Summary
-----------------
The injuries in the dancers are usually associated with different factors such as the characteristics of the footwear, height of the heel and physical requirements, the articulation of the ankle being the most susceptible when the loads are not adequately dealt. The main objective is to evaluate in a sample of subjects if there is a difference in the stability of the ankle, as a consequence of previous sprains, between flamenco dancers and dancers and a dance-free control group.

Detailed Description
-----------------
An observational study. This study has involved a population of 26 subjects divided into two groups of 13 each is studied (40,15 ± 4,675 años); the experimental group is characterized by the practice of flamenco dance

Official Title
-----------------
Ankle Instability in Flamenco Dancers

Conditions
-----------------
Ankle Disease, Dance

Intervention / Treatment
-----------------
* Behavioral: Flamenco dance


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Flamenco dancers - Exclusion Criteria: no

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| experimental group<br>the experimental group is characterized by the practice of flamenco dance | Behavioral: Flamenco dance<br>* evaluation of ankle injuries in the flamenco dancers<br>|
| control group<br>not practice of flamenco dance | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ankle drawer test | Evaluation of the ankle drawer test, in millimeters | A day, the inclusion day in the study | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ankle, dance
Deep Anterior Lamellar Keratoplasty (DALK) Using Acellular Corneal Tissue Promotes Corneal Allograft Survival in High Risk Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to study whether deep anterior lamellar keratoplasty (DALK) using acellular tissue will promote corneal graft survival in high risk patients.

Official Title
-----------------
Deep Anterior Lamellar Keratoplasty Using Acellular Corneal Tissue Promotes Corneal Allograft Survival in High Risk Patients

Conditions
-----------------
Glycerin Cryopreserved Acellular Corneal Tissue, Deep Anterior Lamellar Keratoplasty, High Risk Keratoplasty

Intervention / Treatment
-----------------
* Procedure: DALK using GCCT
* Procedure: DALK using FCT


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: severe bacterial keratitis Herpes simplex keratitis severe fungal keratitis partial limbal deficiency after chemical burn Exclusion Criteria: posterior stroma involved in severe bacterial and fungal keratitis dry eye glaucoma or intraocular pressure greater than 21 mmHg amblyopia retinal abnormalities patients with severe systemic diseases not good for ocular surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: GCCT,corneal allograft survival ,DALK<br>experimental group: deep anterior lamellar keratoplasty using glycerin-cryopreserved corneal tissue | Procedure: DALK using GCCT<br>* Deep anterior lamellar keratoplasty (DALK) using glycerin-cryopreserved corneal tissue<br>* Other names: acellular tissue;|
| Experimental: FCT,corneal allograft survival ,DALK<br>control group: deep anterior lamellar keratoplasty using fresh corneal tissue | Procedure: DALK using FCT<br>* Deep anterior lamellar keratoplasty (DALK) using fresh corneal tissue<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| rejection |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| laser scanning in vivo confocal microscopy |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
deep anterior lamellar keratoplasty, rejection, high risk patients, acellular corneal tissue
Improving Gap Closure Rates Using a Predictive Model

Study Overview
=================
Brief Summary
-----------------
NYU Langone Health outreaches to patients to remind them to schedule their appointments by phone or MyChart message.The proposed study will test different outreach methods using a predictive risk model. The goal is to increase gap closure rate by the end of the year.

Official Title
-----------------
Improving Gap Closure Rates Using a Predictive Model

Conditions
-----------------
Communication, Appointments and Schedules

Intervention / Treatment
-----------------
* Other: Participant outreach


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients in the NYU Langone network who are due for gaps in care. Exclusion Criteria: Patients in the NYU Langone network are not due for gaps in care.

Ages Eligible for Study
-----------------
Minimum Age: 3 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Call center phone call<br>Participants randomized to this arm will receive a phone call from the call center reminding them to schedule their appointments. | Other: Participant outreach<br>* Participants in the experimental arms will receive a call center phone call or MyChart message to remind them to schedule their appointments.<br>|
| No call center phone call<br>Participants randomized to this arm will not receive a phone call from the call center reminding them to schedule their appointments. | |
| MyChart message<br>Participants randomized to this arm will receive an automated MyChart message reminding them to schedule their appointments. | Other: Participant outreach<br>* Participants in the experimental arms will receive a call center phone call or MyChart message to remind them to schedule their appointments.<br>|
| No MyChart message<br>Participants randomized to this arm will not receive an automated MyChart message reminding them to schedule their appointments. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Gap closure rate |  | 1 year |
Seroepidemiological Study of Pertussis and Other Infectious Diseases

Study Overview
=================
Brief Summary
-----------------
Serum samples will be corrected twice from the same youth subjects with one year interval. Seroincidence of pertussis will be estimated by the elevation of Ig-G-PT in paired sera from an identical individual. The relationship between the incidence and the demographic data or medical history of the subjects will be discussed.

Official Title
-----------------
Seroepidemiological Study of Pertussis and Other Infectious Diseases

Conditions
-----------------
Pertussis Infection

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Students of junior high school, high schools or college in Gifu prefecture Students who can have the second blood drawing one year later Students (and their parent when students are underage) whose written consent is obtainable. Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| IgG | Seroincidence of pertussis estimated by the elevation of Ig-G-PT in paired sera(0day, 365day). | 0 day, 365 day (2 points) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of Pertussis | Questionnaire | 0 day | 
| Antibodies of Varicella, Mumps and Rubella | Questionnaire | 0 day | 
| Infection Risk Factors Including Family Numbers, Living Space, With or Without a Cough Patient in the Surroundings, Medical History and Hospitalization | Questionnaire | 365 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pertussis infection, Risk factors
The Reliability of Heart Rate Variability Among Patients With Brain Injury as Measured by POLAR RC810XE Compared to HOLTER

Study Overview
=================
Brief Summary
-----------------
Following a brain injury (BI) in addition to all other systems, there can be a failure in the control of the autonomic system activity. Heart rate (HR) has its own normal variability. Heart rate is controlled by the Sympathetic and Parasympathetic systems. Therefore, monitoring HR variability (HRV) can help us evaluate the balance of the two systems and their efficiency.Decrease in HRV was found to be in correlation with death among patients in the acute stage following ABI. Decrease in HRV is a pre-stage of HR irregularity and ventricular fibrillation.This disturbance can have a great impact on the patients health condition. In addition there was found an inverse correlation between this situation and the rehabilitation outcomes. Based on this data there is a great importance in monitoring HRV during rehabilitation among patients following BI while the patients are required to perform physical activity.The aim of this work is to check whether we can replace the traditional way of measuring HR by EKG Holter (gold standard) with a more simple,accessible tool-the POLAR watch. The aim of this work is to check if the data collected from a POLAR watch is reliable compared to the data collected from an EKG holter.

Official Title
-----------------
The Reliability of Heart Rate Variability Measurements Among Patients With Acquired Brain Injury as Measured During Physical Activity by POLAR RC810XE Compared to HOLTER EKG

Conditions
-----------------
Acquired Brain Injury

Intervention / Treatment
-----------------
* Other: no intervention is made


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Brain Injury Exclusion Criteria: a medical condition which doesn't allow the patient to participate physical activity. patients that can not be there own legal guardian. uncontrolled psychomotoric restlessness.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| brain injury<br> | Other: no intervention is made<br>* no intervention is made<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Heart Rate Variability, Acquired Brain Injury, Physical Activity
Effects on Metabolism and Cognitive Functions of a Commonly Used Commercial Food Supplement

Study Overview
=================
Brief Summary
-----------------
This project evaluate effects of a commonly used food supplement on glucose metabolism and cognitive function.

Detailed Description
-----------------
The test product has previously been suggested to elicit beneficial effects on glucose metabolism and cognitive performance. The purpose with this study is to evaluate metabolic effects and effects on mood variables of the test product provided at breakfast. Test variables are determined at fating and postprandial a standardised breakfast. The results are compared with effects after a placebo product.

Official Title
-----------------
Food Design for Improved Cognitive Performance

Conditions
-----------------
Postprandial Blood Glucose Regulation

Intervention / Treatment
-----------------
* Dietary Supplement: Panax ginseng
* Dietary Supplement: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age between 40-60 years, normal BMI, healthy, non-smokers Exclusion Criteria: metabolic disorders or gastro- intestinal disease, intake of probiotics- or antibiotics during the last 2 weeks prior to the study.

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: test product<br>Arm: Panax ginseng | Dietary Supplement: Panax ginseng<br>* Pananx ginseng is provided prior to a standardised breakfast, effects on test variables are determined at fasting and repeatedly postprandially the breakfast<br>|
| Placebo Comparator: placebo product<br>Arm: a placebo with similar appearance but without Panax ginseng. The tablet include all the other non-active bulk ingredients. | Dietary Supplement: Placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| blood glucose | capillary blood glucose concentrations are determined at fasting and then repeatedly after a standardised breakfast | 4 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| serum insulin | capillary serum insulin concentrations are determined at fasting and then repeatedly after a standardised breakfast | 4 hours | 
| Mood as measured by ratings on 100 mm visual analog scales( VAS rating scales) | measures of 6 mood variables (sad-glad, depressed-happy, displeased-pleased, dull-peppy, passive-Active, sleepy-awake) repeatedly in the postprandial period after breakfast | 4 hours |
Psychiatric Manifestations Associated With Behcet's Disease

Study Overview
=================
Brief Summary
-----------------
The psychoBehçet'study is aimed at evaluating the psychological and neurocognitive symptoms in 25 consecutive patients followed for Behçet's disease. This is a monocentric, observational, non interventional study.

Detailed Description
-----------------
Patients will be evaluated during a day-care facility for Behçet's disease activity together with evaluation of anxiety and depression symptoms (SCL90-R and MINI assessments), fatigue (MFI) and quality of life (SF36).

Official Title
-----------------
Psychiatric Manifestations Associated With Behcet's Disease

Conditions
-----------------
Behçet's Disease, neuroBehcet, Anxiety, Depression, Tiredness

Intervention / Treatment
-----------------
* Other: Questionnaires evaluating anxiety and depression symptoms, tiredness, and quality of life


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult male or female Regular follow-up in the internal medicine department of Bicetre hospital Diagnosed with Behçet's disease Exclusion Criteria: Refusal to participate in the study Poor command of the French language Patients under legal protection Pregnant woman

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patient with Behcet disease<br>adult patient with Behcet's disease followed regularly in the internal medicine department of Bicetre | Other: Questionnaires evaluating anxiety and depression symptoms, tiredness, and quality of life<br>* Realization of specific questionnaires evaluating: psychiatric symptoms (self-assessment according to the SLC-90R questionnaire and hetero-assessment by the internist doctor of the center according to the M.I.N.I. questionnaire) fatigue (Multidimensional Fatigue Inventory (MFI-20), French version, in self-assessment) quality of life (SF36 self-assessment questionnaire)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| SCL90-R questionnaire | Anxiety/depression symptoms questionnaire | Inclusion visit | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| MINI questionnaire | Anxiety/depression symptoms questionnaire | Inclusion visit | 
| MFI questionnaire | Tiredness assessment | Inclusion visit | 
| SF36 questionnaire | Quality of life | Inclusion visit | 
| BSAS/BDCAF evaluation | Behçet's disease activity | Inclusion visit |
Study to Evaluate the Safety and Efficacy of CJ-30060 in Hypertensive Patients With Hyperlipidemia

Study Overview
=================
Brief Summary
-----------------
To evaluate the safety and efficacy of CJ-30060 compared with amlodipine/valsartan combination therapy and valsartan/rosuvastatin combination therapy in hypertensive patients with hyperlipidemia

Official Title
-----------------
A Double-blind, Randomized, Multi-center Phase III Clinical Trial to Evaluate the Safety and Efficacy of CJ-30060 Compared With Amlodipine/Valsartan Combination Therapy and Valsartan/Rosuvastatin Combination Therapy in Hypertensive Patients With Hyperlipidemia

Conditions
-----------------
Hypertension With Hyperlipidemia

Intervention / Treatment
-----------------
* Drug: Amlodipine 10 mg + Valsartan 160 mg + Rosuvastatin 20 mg
* Drug: Amlodipine 10 mg + Valsartan 160 mg
* Drug: Valsartan 160 mg + Rosuvastatin 20 mg


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aged between 19 and 74 years Patient with dyslipidemia and hypertension Exclusion Criteria: At screening, siSBP ≥ 200 mmHg or siDBP ≥ 120mmHg or LDL-C > 250mg/dL or TG ≥ 400mg/dL At screening, siSBP difference is ≥ 20 mmHg or siDBP difference is ≥10 mmHg Secodary hypertension Type I or uncontrolled diabetes mellitus (HbA1c ≥ 9 %)

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 74 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Test<br>Amlodipine 10mg + Valsartan 160mg + Rosuvastatin 20mg | Drug: Amlodipine 10 mg + Valsartan 160 mg + Rosuvastatin 20 mg<br> <br> |
| Active Comparator: Reference 1<br>Amlodipine 10mg + Valsartan 160mg | Drug: Amlodipine 10 mg + Valsartan 160 mg<br> <br> |
| Active Comparator: Reference 2<br>Valsartan 160mg + Rosuvastatin 20mg | Drug: Valsartan 160 mg + Rosuvastatin 20 mg<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change of LDL-C and siSBP | Mean change from baseline in LDL-C and siSBP at Week 8 | baseline and 8 weeks |
Conventional and Experimental Chemotherapy With Allogeneic Transplant in Young Patients With Acute Myeloid Leukaemia

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is evaluate patients with acute myeloid leukemia (<=66 years), treated with conventional and experimental chemotherapy following allogeneic transplantation. THis patients have been enrolled from 2000 to 2011 at the Division of Hematology, Molinette University Hospital. The purpose of data collection is to assess, with retrospective analysis, the clinical outcome divided by risk class and evaluated in patients who achieve complete remission after induction therapy and consolidation.

Official Title
-----------------
CONVENTIONAL AND EXPERIMENTAL CHEMOTHERAPY WITH ALLOGENEIC TRANSPLANT IN YOUNG PATIENTS WITH ACUTE MYELOID LEUKAEMIA

Conditions
-----------------
Acute Myeloid Leukemia

Participation Criteria
=================
Eligibility Criteria
-----------------
Patients with acute myeloid leukemia (<=66 years), treated with conventional and experimental chemotherapy following allogeneic transplantation. THis patients have been enrolled from 2000 to 2011 at the Division of Hematology, Molinette University Hospital.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 66 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival |  | 1 year | 
| Event-free survival |  | 1 year |